P53: A Guardian of Immunity Becomes Its Saboteur through Mutation
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Awareness of the importance of immunity in controlling cancer development triggered research into the impact of its key oncogenic drivers on the immune response, as well as their value as targets for immunotherapy. At the heart of tumour suppression is p53, which was discovered in the context of viral infection and now emerges as a significant player in normal and cancer immunity. Wild-type p53 (wt p53) plays fundamental roles in cancer immunity and inflammation. Mutations in p53 not only cripple wt p53 immune functions but also sinisterly subvert the immune function through its neomorphic gain-of-functions (GOFs). The prevalence of mutant p53 across different types of human cancers, which are associated with inflammatory and immune dysfunction, further implicates mutant p53 in modulating cancer immunity, thereby promoting tumorigenesis, metastasis and invasion. In this review, we discuss several mutant p53 immune GOFs in the context of the established roles of wt p53 in regulating and responding to tumour-associated inflammation, and regulating innate and adaptive immunity. We discuss the capacity of mutant p53 to alter the tumour milieu to support immune dysfunction, modulate toll-like receptor (TLR) signalling pathways to disrupt innate immunity and subvert cell-mediated immunity in favour of immune privilege and survival. Furthermore, we expose the potential and challenges associated with mutant p53 as a cancer immunotherapy target and underscore existing therapies that may benefit from inquiry into cancer p53 status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · cited 4×
“This similarly applies to the host’s initial response to the danger signals from a developing tumour and cancer-associated inflammation [130].”
BackgroundInfluentialOxidative stress, inflammation, and cancer: How are they linked?
Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.09.006 · Cited by 5,441
Role of nrf2 in oxidative stress and toxicity
Ma, Q. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140320 · Cited by 4,903 · cited 1×
“Mutant p53 may also impinge on endogenous antioxidant systems by differentially regulating components of the NRF2 transcriptional program responsible for the expression of antioxidant response element-dependent genes [70].”
BackgroundSTATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383 · cited 1×
“STAT3, and, in some cases, STAT5 and STAT6, affect the TME by promoting immunosuppressive TMEs and inhibiting anti-tumour immunity [49,50].”
BackgroundOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
The Tumor Microenvironment Innately Modulates Cancer Progression
Hinshaw, D. C., & Shevde, L. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3962 · Cited by 3,270
Erez, N., Truitt, M., Olson, P., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.041 · Cited by 1,515 · cited 1×
“cells can “educate” normal fibroblasts gradually to adopt CAF-like properties [93].”
BackgroundMittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
The role of cyclooxygenases in inflammation, cancer, and development
Williams, C. S., Mann, M., & DuBois, R. N. (1999) · Oncogene · doi:10.1038/sj.onc.1203286 · Cited by 1,417
Role of tumor microenvironment in tumorigenesis
Wang, M., Zhao, J., Zhang, L., Wei, F., Lian, Y., Wu, Y., Gong, Z., Zhang, S., Zhou, J., Cao, K., et al. (2017) · Journal of Cancer · doi:10.7150/jca.17648 · Cited by 1,404
Talks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., & Harris, A. L. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64554-3 · Cited by 1,312
Immunogenic and tolerogenic cell death
Green, D. R., Ferguson, T., Zitvogel, L., & Kroemer, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2545 · Cited by 1,176
Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer
Grivennikov, S. I., & Karin, M. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.005 · Cited by 1,160
Chien, Y., Scuoppo, C., Wang, X., Fang, X., Balgley, B., Bolden, J. E., Premsrirut, P., Luo, W., Chicas, A., Lee, C. S., et al. (2011) · Genes & Development · doi:10.1101/gad.17276711 · Cited by 1,046 · cited 2×
“NF-κB can participate in wt p53-mediated apoptosis [35] and cooperate with wt p53 to promote senescence in IMR-90 cells but not human BJ fibroblasts [36].”
BackgroundCensus and evaluation of p53 target genes
Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · Genes & Development · doi:10.1101/gad.14.1.34 · Cited by 967
Unmasking senescence: context-dependent effects of SASP in cancer
Faget, D. V., Ren, Q., & Stewart, S. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0156-2 · Cited by 863 · cited 1×
“The effects of SASP on cancer is mediated primarily through the inflammatory phenotype and the consequent changes in cellular signalling it produces, which have been extensively reviewed elsewhere [25,26].”
BackgroundTakaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., et al. (2003) · Nature · doi:10.1038/nature01850 · Cited by 847
Non-Cell-Autonomous Tumor Suppression by p53
Lujambio, A., Akkari, L., Simon, J., Grace, D., Tschaharganeh, D. F., Bolden, J. E., Zhao, Z., Thapar, V., Joyce, J. A., Krizhanovsky, V., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.020 · Cited by 766 · cited 1×
“The loss of wt p53 activity in CAFs can further exert selective pressure to promote transformation in neighbouring epithelial cells through ablation of p53-dependent senescence programs and skewed macrophage polarisation (Figure 2B) [91].”
BackgroundThe senescence-associated secretory phenotype and its regulation
Lopes-Paciencia, S., Saint-Germain, E., Rowell, M.-C., Ruiz, A. F., Kalegari, P., & Ferbeyre, G. (2019) · Cytokine · doi:10.1016/j.cyto.2019.01.013 · Cited by 601
Transcriptional Cross Talk between NF-κB and p53
Webster, G. A., & Perkins, N. D. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3485 · Cited by 598
Ostrand-Rosenberg, S., Sinha, P., Beury, D. W., & Clements, V. K. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.01.011 · Cited by 583
Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis
Wellenstein, M. D., Coffelt, S. B., Duits, D. E. M., van Miltenburg, M. H., Slagter, M., de Rink, I., Henneman, L., Kas, S. M., Prekovic, S., Hau, C.-S., et al. (2019) · Nature · doi:10.1038/s41586-019-1450-6 · Cited by 500
Ilić, D., Almeida, E. A. C., Schlaepfer, D. D., Dazin, P., Aizawa, S., & Damsky, C. H. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.2.547 · Cited by 495 · cited 1×
“Previous studies have demonstrated that the ECM can exert a regulatory effect on the p53 activity of cultured cells through pro-survival signals that suppress its apoptotic functions [102,103].”
BackgroundMutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling
Weissmueller, S., Manchado, E., Saborowski, M., Morris, J. P., Wagenblast, E., Davis, C. A., Moon, S.-H., Pfister, N. T., Tschaharganeh, D. F., Kitzing, T., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.066 · Cited by 466 · cited 1×
“Moreover, Arf6 activation is facilitated by the platelet-derived growth factor (PDGF), a product of TLR4 signalling, and its β receptor (PDGFRβ), a direct target of mutant p53 [178,186,187].”
BackgroundCancer-Associated Fibroblasts Build and Secure the Tumor Microenvironment
Liu, T., Zhou, L., Li, D., Andl, T., & Zhang, Y. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00060 · Cited by 446
Iannello, A., Thompson, T. W., Ardolino, M., Lowe, S. W., & Raulet, D. H. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130783 · Cited by 414
Senescence-associated inflammatory responses: aging and cancer perspectives
Lasry, A., & Ben-Neriah, Y. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.009 · Cited by 408 · cited 1×
“The effects of SASP on cancer is mediated primarily through the inflammatory phenotype and the consequent changes in cellular signalling it produces, which have been extensively reviewed elsewhere [25,26].”
BackgroundSchwitalla, S., Ziegler, P. K., Horst, D., Becker, V., Kerle, I., Begus-Nahrmann, Y., Lechel, A., Rudolph, K. L., Langer, R., Slotta-Huspenina, J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.014 · Cited by 296
Korniluk, A., Koper, O., Kemona, H., & Dymicka-Piekarska, V. (2017) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-016-1464-0 · Cited by 282 · cited 1×
“Chronic inflammation stokes environmental and genetic stress, which fuels tumorigenesis [21].”
BackgroundTextor, S., Fiegler, N., Arnold, A., Porgador, A., Hofmann, T. G., & Cerwenka, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3211 · Cited by 221
Guo, G., Yu, M., Xiao, W., Celis, E., & Cui, Y. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2832 · Cited by 168 · cited 2×
“Indeed, the efficacy of the reactivation is p53-dependent, not only in the tumour but also in the leukocyte population within the TME [46].”
BackgroundPaone, A., Starace, D., Galli, R., Padula, F., De Cesaris, P., Filippini, A., Ziparo, E., & Riccioli, A. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn149 · Cited by 160 · cited 1×
“This modulation of TLR3 responsiveness is directly attributed to the presence of transcriptionally active or TLR3-enhancing p53 mutants like P151H and R337H, while other mutants may conversely dampen the TLR3-mediated immune response [145,175,176].”
BackgroundIFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression
Thiem, A., Hesbacher, S., Kneitz, H., di Primio, T., Heppt, M. V., Hermanns, H. M., Goebeler, M., Meierjohann, S., Houben, R., & Schrama, D. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1403-9 · Cited by 153 · cited 1×
“P53 transactivates programmed death-ligand 1 (PD-L1) and its receptor programmed death-1 (PD-1) in cancer cells, and in normal T cells in response to stress [213,214].”
BackgroundHashimoto, S., Furukawa, S., Hashimoto, A., Tsutaho, A., Fukao, A., Sakamura, Y., Parajuli, G., Onodera, Y., Otsuka, Y., Handa, H., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901765116 · Cited by 149
Cross talk between stimulated NF-κB and the tumor suppressor p53
Schneider, G., Henrich, A., Greiner, G., Wolf, V, Lovas, A., Wieczorek, M., Wagner, T., Reichardt, S., von Werder, A., Schmid, R. M., et al. (2010) · Oncogene · doi:10.1038/onc.2010.46 · Cited by 149
The Toll-like receptor gene family is integrated into human DNA damage and p53 networks
Menendez, D., Shatz, M., Azzam, K., Garantziotis, S., Fessler, M. B., & Resnick, M. A. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001360 · Cited by 148
Shatz, M., Menendez, D., & Resnick, M. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4134 · Cited by 143 · cited 2×
“Wt p53 regulates the expression of the TLR gene family in T-lymphocytes, and to a lesser extent in macrophages, in a manner dependent on the genetic stress and the host genetic context [144,158,159].”
Backgroundp53 regulates Toll-like receptor 3 expression and function in human epithelial cell lines
Taura, M., Eguma, A., Suico, M. A., Shuto, T., Koga, T., Komatsu, K., Komune, T., Sato, T., Saya, H., Li, J.-D., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01202-08 · Cited by 129
P53 and The Immune Response: 40 Years of Exploration—A Plan for the Future
Levine, A. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020541 · Cited by 97
Ubertini, V, Norelli, G., D'Arcangelo, D., Gurtner, A., Cesareo, E., Baldari, S., Gentileschi, M. P., Piaggio, G., Nisticò, P., Soddu, S., et al. (2015) · Oncogene · doi:10.1038/onc.2014.191 · Cited by 75 · cited 1×
“For example, the suppression of the anti-inflammatory cytokine sIL-1RA by mutant p53 results in chronic inflammation associated with tumour progression [76].”
BackgroundNutlin-3 inhibits the NFκB Pathway in a p53 Dependent Manner: Implications in Lung Cancer Therapy
Dey, A., Wong, E. T., Bist, P., Tergaonkar, V., & Lane, D. (2007) · Cell Cycle · doi:10.4161/cc.6.17.4643 · Cited by 70
TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis
Taura, M., Fukuda, R., Suico, M. A., Eguma, A., Koga, T., Shuto, T., Sato, T., Morino‐Koga, S., & Kai, H. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01567.x · Cited by 69
Regulation of MCP-1 chemokine transcription by p53
Hacke, K., Rincon-Orozco, B., Buchwalter, G., Siehler, S. Y., Wasylyk, B., Wiesmüller, L., & Rösl, F. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-82 · Cited by 63
Ligand dependent restoration of human TLR3 signaling and death in p53 mutant cells
Menendez, D., Lowe, J. M., Snipe, J., & Resnick, M. A. (2016) · Oncotarget · doi:10.18632/oncotarget.11210 · Cited by 31 · cited 7×
“This modulation of TLR3 responsiveness is directly attributed to the presence of transcriptionally active or TLR3-enhancing p53 mutants like P151H and R337H, while other mutants may conversely dampen the TLR3-mediated immune response [145,175,176].”
BackgroundInfluentialShatz, M., Shats, I., Menendez, D., & Resnick, M. A. (2015) · Oncotarget · doi:10.18632/oncotarget.4435 · Cited by 29
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
“188 49,87,189 – 192 In the process of tumor development, p53 suppresses tumor transformation, 22 proliferation, 193 metastasis 194 and drug resistance 195 through multifaceted regulation. p53 has an exceptionally fl exible biological response that is altered by changes in cell type, cell…”
Backgroundp53 signaling in cancer progression and therapy
Marei, H. E., Althani, A., Afifi, N., Hasan, A., Caceci, T., Pozzoli, G., Morrione, A., Giordano, A., & Cenciarelli, C. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02396-8 · Cited by 588
The Regulation of Ferroptosis by Tumor Suppressor p53 and its Pathway
Liu, J., Zhang, C., Wang, J., Hu, W., & Feng, Z. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218387 · Cited by 249
Translating p53-based therapies for cancer into the clinic
Peuget, S., Zhou, X., & Selivanova, G. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-023-00658-3 · Cited by 190
Metadata
- Authors
- Agupitan, A. D., Neeson, P., Williams, S., Howitt, J., Haupt, S., & Haupt, Y.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-05-13
- Volume
- 21
- Issue
- 10
- Pages
- 3452
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3024744974
- Cited by
- 99
- References
- 46
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.